Angiotensin-converting enzyme inhibitors: considerations regarding proteinuria.
The effects of captopril on renal function are evaluated in hypertensive patients with impaired renal function previously entered in a worldwide surveillance study. For the overwhelming majority of patients, control of BP was accompanied by stable or improved renal function. To date, the major adverse renal reactions have been a somewhat increased risk of worsening proteinuria among these patients and the well-documented acute decrease in renal function that may occur in patients with bilateral renal artery stenosis.
D000806:Angiotensin-Converting Enzyme Inhibitors; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000009:adverse effects* / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D006978:Hypertension, Renovascular / Q000188:drug therapy; D009404:Nephrotic Syndrome / Q000139:chemically induced; D011507:Proteinuria / Q000139:chemically induced*; D012306:Risk
D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril